Longitudinal biomarker analysis of infants treated with multiple courses of gentamicin without a change in serum creatinine concentration.

<p>Representative figures demonstrating the longitudinal quantification of the biomarkers KIM-1 (blue; ng/mg. uCr), NGAL (green; ng/mg. uCr), NAG (yellow; IU/mg. uCr) and serum creatinine (red; µmol/L) for three infants treated with gentamicin (A–C). Gentamicin treatment episode and length of treatment (days) are indicated by the black horizontal bar on each figure for that individual patient.</p

Baseline characteristics and clinical signs of neonates treated with gentamicin.

<p>Patients are subdivided according to gestational age. Mean biomarker values presented include samples collected both on and off gentamicin treatment over the whole time course of inclusion in the study.</p

Longitudinal biomarker analysis of infants treated with multiple courses of gentamicin with a change in serum creatinine concentration (AKI).

<p>Representative figures demonstrating the longitudinal quantification of the biomarkers KIM-1 (blue; ng/mg. uCr), NGAL (green; ng/mg. uCr), NAG (yellow; IU/mg. uCr) and serum creatinine (red; µmol/L) for three infants treated with gentamicin (A–C). Gentamicin treatment episode and length of treatment (days) are indicated by the black horizontal bar on each figure for that individual patient.</p

Association between gentamicin treatment and the change in biomarker values.

<p>The mean baseline biomarker values in the absence of any gentamicin treatment were 1.91 ng/mg uCr (95% CI 1.07, 2.76) for KIM-1, 0.13 IU/mg uCr (0.07, 0.19) for NAG, 425.4 ng/mg uCr (162.6, 688.3) for NGAL, and 62.39 µmol/l (53.1, 71.69) for creatinine.</p